QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.105.008375v1 34/5/743    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tahara, H. Articles by Sugiyama, Y. Search for Related Content PubMed PubMed Citation Articles by Tahara, H. Articles by Sugiyama, Y.

INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID

Graduate School of Pharmaceutical Sciences, University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan (H.T., H.Ku., K.M., Y.S.); Pharmacokinetic Research Laboratories, Pharmaceutical Research Institute, Kyowa Hokko Kogyo Co., Ltd., Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan (H.T., E.F.); and Institut für Anatomie und Zellbiologie, Universität Würzburg, Germany (H.Ko.)

Fexofenadine, a nonsedating antihistamine drug, is effective for the treatment of seasonal allergic rhinitis and chronic urticaria. Simultaneous administration of probenecid increases the plasma concentration of fexofenadine due to an inhibition of its renal elimination in healthy volunteers (Clin Pharmacol Ther 77:17–23, 2005). The purpose of the present study is to investigate the possibility that the drug-drug interaction between fexofenadine and probenecid involves the renal basolateral uptake process. The uptake of fexofenadine was determined in HEK293 cells expressing human organic anion transporter 1 (OAT1/SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8), and organic cation transporter 2 (OCT2/SLC22A2). Only hOAT3-HEK showed a significantly greater accumulation of fexofenadine than that in vector-HEK, which was saturable with K_m and V_max values of 70.2 µM and 120 pmol/min/mg protein, respectively. Inhibition potency of probenecid for the uptake of fexofenadine was compared between hOAT3 and organic anion-transporting peptide 1B3 (hOATP1B3), a transporter responsible for the hepatic uptake of fexofenadine (Drug Metab Dispos 33:1477–1481, 2005). The K_i values were determined to be 1.30 and 130 µM for hOAT3 and hOATP1B3, respectively, with Hill coefficients of 0.76 and 0.64, respectively. The K_i value of probenecid for hOAT3, but not for hOATP1B3, was significantly lower than the maximum unbound plasma concentration of probenecid at clinical dosages. These results suggest that the renal drug-drug interaction between fexofenadine and probenecid is probably explained by an inhibition of the renal uptake of fexofenadine via hOAT3, at least in part.

This article has been cited by other articles:

				S. Hu, Z. Chen, R. Franke, S. Orwick, M. Zhao, M. A. Rudek, A. Sparreboom, and S. D. Baker Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters Clin. Cancer Res., October 1, 2009; 15(19): 6062 - 6069. [Abstract] [Full Text] [PDF]

				H. Yuan, B. Feng, Y. Yu, J. Chupka, J. Y. Zheng, T. G. Heath, and B. R. Bond Renal Organic Anion Transporter-Mediated Drug-Drug Interaction between Gemcabene and Quinapril J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 191 - 197. [Abstract] [Full Text] [PDF]

				S. Matsushima, K. Maeda, K. Inoue, K.-y. Ohta, H. Yuasa, T. Kondo, H. Nakayama, S. Horita, H. Kusuhara, and Y. Sugiyama The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine Drug Metab. Dispos., March 1, 2009; 37(3): 555 - 559. [Abstract] [Full Text] [PDF]

				T. Uemura, H. F. Yerushalmi, G. Tsaprailis, D. E. Stringer, K. E. Pastorian, L. Hawel III, C. V. Byus, and E. W. Gerner Identification and Characterization of a Diamine Exporter in Colon Epithelial Cells J. Biol. Chem., September 26, 2008; 283(39): 26428 - 26435. [Abstract] [Full Text] [PDF]

				S. Liu, P. M. Beringer, L. Hidayat, A. P. Rao, S. Louie, G. J. Burckart, and B. Shapiro Probenecid, but Not Cystic Fibrosis, Alters the Total and Renal Clearance of Fexofenadine J. Clin. Pharmacol., August 1, 2008; 48(8): 957 - 965. [Abstract] [Full Text] [PDF]

				S. Hu, R. M. Franke, K. K. Filipski, C. Hu, S. J. Orwick, E. A. de Bruijn, H. Burger, S. D. Baker, and A. Sparreboom Interaction of Imatinib with Human Organic Ion Carriers Clin. Cancer Res., May 15, 2008; 14(10): 3141 - 3148. [Abstract] [Full Text] [PDF]

				S. Matsushima, K. Maeda, N. Ishiguro, T. Igarashi, and Y. Sugiyama Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans Drug Metab. Dispos., April 1, 2008; 36(4): 663 - 669. [Abstract] [Full Text] [PDF]

				P. Acharya, M. P. O'Connor, J. W. Polli, A. Ayrton, H. Ellens, and J. Bentz Kinetic Identification of Membrane Transporters That Assist P-glycoprotein-Mediated Transport of Digoxin and Loperamide through a Confluent Monolayer of MDCKII-hMDR1 Cells Drug Metab. Dispos., February 1, 2008; 36(2): 452 - 460. [Abstract] [Full Text] [PDF]

				A. L. VanWert, R. M. Bailey, and D. H. Sweet Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1332 - F1341. [Abstract] [Full Text] [PDF]